- Home
- JAGX
JAGX
Jaguar Health Inc.
as 03-31-2025 12:39pm EST
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | SAN FRANCISCO |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 37.1K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -205.60 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.90 - $540.00 | Next Earning Date: | 05-13-2025 |
| Revenue: | $10,480,000 | Revenue Growth: | -2.25% |
| Revenue Growth (this year): | 18.18% | Revenue Growth (next year): | 40.06% |
Latest Jaguar Health Inc. News
JAGX Breaking Stock News: Dive into JAGX Ticker-Specific Updates for Smart Investing
ACCESS Newswire
5 hours ago
Jaguar Health Reports 2024 Financials: 2024 Net Revenue Up Approximately 20% Over 2023
ACCESS Newswire
3 days ago
83.33% of Veterinary Oncologists Highlight Importance of Jaguar Health's FDA Conditionally Approved Canalevia-CA1 as a Non-Antibiotic Treatment for Chemotherapy-Induced Diarrhea (CID) in Dog's in New Survey
ACCESS Newswire
4 days ago
Jaguar Health Meeting with FDA Regarding Results of Phase 3 OnTarget Study
MT Newswires
5 days ago
Sector Update: Health Care
ACCESS Newswire
5 days ago
Jaguar Health Presenting March 27 at Emerging Growth Conference and Holding Investor Webcast March 31 Regarding Q4 2024 Financials & Near-Term Catalysts
MT Newswires
5 days ago
Jaguar Health Executives Invest in $3.5 Million Bridge Financing; Shares Fall
ACCESS Newswire
5 days ago
Jaguar Health CEO, Board Members, Other C-Suite Members, and Institutional and Accredited Investors Invest in $3.448 Million Bridge Financing Priced At-The-Market Under Nasdaq Rules
GlobeNewswire
5 days ago
Presenting on the Emerging Growth Conference 80 Day 2 on March 27 Register Now
Compare JAGX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "JAGX Jaguar Health Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.